Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Starts China Phase III Trial of HER2 Conjugate Drug

publication date: Nov 2, 2018

Bio-Thera Solutions of Guangzhou has started a China Phase III trial of its HER2 antibody-drug conjugate (BAT8001) in patients with HER-2 positive metastatic breast cancer. The trial will compare BAT8001 to a lapatinib-capecitabine combination, a second-line standard of care for metastatic breast cancer. Bio-Thera is testing BAT8001 in several tumor types that overexpress HER2, especially breast and gastric cancer. The company has five candidates in late-stage clinical trials and a China NDA in review for a Humira biosimilar. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital